GLI1 and cancer: Furthermore, we describe the identification of the novel CSNK1D inhibitor CK1D008 and show that pharmacological targeting of CSNK1D with potent small molecule inhibitors including CK1D008 and SR-3029 [68] abolishes oncogenic HH—GLI signaling in distinct cancer entities with either SMO-dependent or SMO-independent oncogenic GLI activity.